Table 1.
Properties of anti-A2 mAbs
| mAbs | BU/mg IgG | Type | Isotype | Group | Epitope | |
|---|---|---|---|---|---|---|
| 1 | 4A4 | 40 000 | I | IgG2aκ | A | Asp403-His444 |
| 2 | 2-76 | 38 000 | I | IgG2aκ | A | Arg484-Ile508 |
| 3 | G32 | 3 000 | I | IgG2aκ | A | His444-Ile508 |
| 4 | I62 | 15 000 | I | IgG2aκ | A | Arg484-Ile508 |
| 5 | I155 | 40 000 | I | IgG1κ | A | Arg484-Ile508 |
| 6 | I160 | 20 000 | I | IgG2aκ | A | Arg484-Ile508 |
| 7 | 413 | 21 000 | I | IgG1κ | A | Arg484-Ile508 |
| 8 | G119 | 10 000 | I | IgG1κ | A | Arg484-Ile508 |
| 9 | 2-105 | 40 000 | I | IgG1κ | A | Arg484-Ile508 |
| 10 | B157 | <1 | N/A* | IgG1κ | AB | Indeterminate |
| 11 | 2-93 | 4 | II | IgG1κ | B | Arg541-Glu604 |
| 12 | B107 | Indeterminate† | II | IgG2aκ | B | Arg541-Glu604 |
| 13 | 4F4 | 330 | I | IgG2aκ | B | Indeterminate |
| 14 | G139 | <1 | N/A* | IgG1κ | B | Arg541-Glu604 |
| 15 | B94 | Indeterminate† | II | IgG1κ | B | Arg541-Glu604 |
| 16 | G6 | NI | N/A* | IgG2aκ | B | His444-Ile508 |
| 17 | G4 | 9 | I | IgG1κ | B | Arg541-Glu604 |
| 18 | B99 | 11 | I | IgG1κ | BCD | Indeterminate |
| 19 | G48 | 5 | II | IgG2aκ | C | His444-Arg541 |
| 20 | B25 | 100 | I | IgG1κ | C | His444-Gln468 |
| 21 | 2-54 | 34 000 | II | IgG1κ | D | Glu604-Arg740 |
| 22 | CLB-CAg 9 | Indeterminate† | II | IgG1κ | D | Glu604-Arg740 |
| 23 | GMA-012 | <1 | N/A* | IgG1κ | D | Glu604-Arg740 |
| 24 | G74 | 1 500 | I | IgG1κ | DE | Glu604-Arg740 |
| 25 | 1D4 | 7 000 | I | IgG2aκ | E | Glu604-Arg740 |
| 26 | B66 | 4 000 | I | IgG2aκ | E | Glu604-Arg740 |
| 27 | B161 | 150 | I | IgG2aκ | E | Glu604-Arg740 |
| 28 | 4C7 | <1 | N/A* | IgG2aƙ | E | Indeterminate |
| 29 | 2G10 | Indeterminate† | II | IgG2aƙ | E | Indeterminate |
*Not applicable to noninhibitory mAbs.
†Residual fVIII activity at saturating concentrations of Ab was >50%.